Pickering emulsion for realizing efficient delivery of immunologic adjuvant monophosphoryl lipid A as well as preparation method and application of Pickering emulsion

By using Pickering emulsion in vaccines, the single molecule delivery of the immune adjuvant monophosphoryl lipid A was solved, the problem of insufficient immunogenicity of subunit protein antigen was enhanced, the recognition efficiency of TLR4 receptor was achieved, and the efficiency of efficient Cellular immune response and stable vaccine preparation.

CN119015408AInactive Publication Date: 2024-11-26SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Patent Information

Application Number
CN202411032731.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Among the existing vaccines, the immunogenicity of subunit protein antigen is weak, and it is difficult to stimulate an ideal immune response by using alone. A simple mixture of immune adjuvants and antigens cannot effectively induce an ideal immune response, mainly because the immune system is immune to vaccine dosage forms. Dependence on adjuvant and antigen delivery capabilities.

Method used

Using Pickering emulsion, the single molecule dynamic delivery of the immune adjuvant monophosphoryl lipid A and polymer nanoparticles is achieved by dispersing monophosphoryl lipid A at the oil-water interface, enhancing its contact and recognition efficiency with TLR4 receptors. , induce efficient cellular immune response.

Benefits of technology

Improves the contact and recognition efficiency between the immune adjuvant monophosphoryl lipid A and TLR4 receptor, enhances the cellular immune response, and Pickering emulsion is highly safe and stable, suitable for vaccines and anti-tumor drugs. Preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015408A_ABST
    Figure CN119015408A_ABST
Patent Text Reader

Abstract

The invention provides a Pickering emulsion for realizing high-efficiency delivery of immunologic adjuvant monophosphoryl lipid A. The Pickering emulsion belongs to the technical field of biological medicines and comprises an oil phase, a water phase, monophosphoryl lipid A, polymer nanoparticles and polypeptide antigens, the polymer nanoparticles are dispersed on an oil-water interface of the water phase and the oil phase, and the polypeptide antigens are dispersed on the oil-water interface of the water phase and the oil phase. The monophosphoryl lipid A is stably distributed on an oil-water interface of the water phase and the oil phase in a single molecule form and can flow along the oil-water interface. The Pickering emulsion can realize single-molecule dynamic delivery of the immunologic adjuvant monophosphoryl lipid A, so that the contact and recognition efficiency between the monophosphoryl lipid A and a TLR4 receptor is enhanced, and efficient cellular immune response is induced. The invention also provides a preparation method and application of the Pickering emulsion for realizing efficient delivery of the immunologic adjuvant monophosphoryl lipid A.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and particularly relates to a Pickering emulsion for achieving efficient delivery of immune adjuvant monophosphoryl lipid A, and a preparation method and application thereof. Background Art

[0002] As the requirements for vaccine safety become higher and higher, vaccines are gradually transitioning from attenuated inactivated vaccines to subunit protein vaccines. However, the immunogenicity of subunit protein antigens is weak, and it is difficult to stimulate the body to produce an ideal immune response level when used alone. Therefore, immune adjuvants are often added to enhance and regulate the immunogenicity of antigens without increasing side effects. Immune adjuvants are key components of vaccines, which can enhance the level of immune response or change the type of immune response by stimulating the activation of the body's immune cells. In addition, the rational use of immune adjuvants can also effectively reduce the amount of antigen used and the number of immunizations, thereby further reducing the degree and probability of side effects. It is worth noting that simply mixing immune adjuvants and antigens cannot induce an ideal immune response, mainly because the specific activation efficiency of the immune system fully depends on the strength of the vaccine dosage form's ability to deliver immune adjuvants and antigens together. Therefore, how to achieve efficient delivery of immune adjuvants and antigens is a key scientific and engineering problem that needs to be solved in the development of vaccine products. Summary of the invention

[0003] In order to improve the delivery efficiency of vaccine immune adjuvants, the present invention provides a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A. The Pickering emulsion can achieve single-molecule dynamic delivery of the immune adjuvant monophosphoryl lipid A, thereby enhancing the contact and recognition efficiency between monophosphoryl lipid A and TLR4 receptor, thereby inducing an efficient cellular immune response.

[0004] The present invention also provides a preparation method and application of a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A.

[0005] The present invention is achieved through the following technical solutions:

[0006] The present invention provides a Pickering emulsion for realizing efficient delivery of monophosphoryl lipid A as an immune adjuvant. The Pickering emulsion comprises an oil phase, an aqueous phase, monophosphoryl lipid A, polymer nanoparticles and polypeptide antigens. The polymer nanoparticles and the polypeptide antigens are dispersed at the oil-water interface between the aqueous phase and the oil phase. The monophosphoryl lipid A is stably distributed at the oil-water interface between the aqueous phase and the oil phase in the form of a single molecule and can flow laterally along the oil-water interface.

[0007] Optionally, the oil phase includes squalene and / or tocopherol, and the aqueous phase includes any one of water, phosphate buffer, citrate buffer and physiological saline.

[0008] Furthermore, the polymer nanoparticles include at least one of PLGA (poly(lactic-co-glycolic acid)) nanoparticles, PEG-modified PLGA nanoparticles, liposomes and ferritin.

[0009] Furthermore, the polypeptide antigen is chemically modified, and the chemical modification includes at least one of alkylation modification, perfluoroalkylation modification, palmitic acid modification, sugar chain modification and PEG (polyethylene glycol) modification.

[0010] Furthermore, the Pickering emulsion is an oil-in-water emulsion, and the average particle size of the Pickering emulsion is 500 nm to 5 μm;

[0011] The concentration of the polymer nanoparticles in the Pickering emulsion is 0.1 to 1.0 wt %.

[0012] Based on the same inventive concept, the present invention provides a method for preparing a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A, the preparation method comprising:

[0013] Adding monophosphoryl lipid A to the oil phase, and using a water bath ultrasound method to completely disperse the monophosphoryl lipid A to obtain a monophosphoryl lipid A-oil phase dispersion;

[0014] adding the monophosphoryl lipid A-oil phase dispersion to an aqueous solution containing polymer nanoparticles and polypeptide antigens to obtain a mixed solution;

[0015] The mixed solution is ultrasonically emulsified to obtain a Pickering emulsion that can achieve efficient delivery of the immune adjuvant monophosphoryl lipid A.

[0016] Furthermore, in the monophosphoryl lipid A-oil phase dispersion, the mass concentration of the monophosphoryl lipid A is 0.01 to 0.1%;

[0017] In the aqueous solution containing polymer nanoparticles and polypeptide antigens, the mass concentration of the polymer nanoparticles is 0.11% to 1.1%, and the mass concentration of the polypeptide antigen is 0.003% to 0.03%;

[0018] The volume ratio of the monophosphoryl lipid A-oil phase dispersion to the aqueous solution containing polymer nanoparticles and polypeptide antigens is 1:9.

[0019] Based on the same inventive concept, the present invention also provides a use of a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A in the preparation of infectious disease vaccines or anti-tumor drugs.

[0020] Furthermore, the infectious disease includes any one of influenza, hepatitis B and hand, foot and mouth disease.

[0021] Furthermore, the anti-tumor drug includes a drug for preventing or treating any one of lung cancer, melanoma, breast cancer, esophageal cancer, colon cancer, liver cancer and cervical cancer.

[0022] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0023] 1. The present invention discloses a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A, wherein the immune adjuvant monophosphoryl lipid A is stably distributed at the oil-water interface of the Pickering emulsion in the form of a single molecule and can flow laterally at the oil-water interface, thereby enhancing the contact and recognition efficiency between the monophosphoryl lipid A and the TLR4 receptor on the surface of antigen presenting cells, thereby inducing an efficient cellular immune response. The Pickering emulsion of the present invention can be used to prepare vaccines, and has the advantages of good safety, high stability, and the ability to induce an efficient cellular immune response.

[0024] 2. The present invention discloses a method for preparing a Pickering emulsion that can achieve efficient delivery of monophosphoryl lipid A, an immune adjuvant. The Pickering emulsion prepared by the method can achieve single-molecule delivery and recognition of monophosphoryl lipid A, thereby enhancing the contact and recognition efficiency between monophosphoryl lipid A and TLR4 receptor. The multi-level structure (nanoparticles, oil phase core and oil-water interface) of the Pickering emulsion can provide a structural basis for the co-loading and coordinated delivery of monophosphoryl lipid A and polypeptide antigens. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 The scanning electron micrograph (left) and particle size distribution diagram (right) of the Pickering emulsion loaded with monophosphoryl lipid A in Example 1.

[0027] Figure 2 The figure shows the effect of the existence form of monophosphoryl lipid A at the oil-water interface of Pickering emulsion in Example 2 on the secretion of TNF-α by macrophages.

[0028] Figure 3 The maturation and activation of DC cells after treatment with the vaccine formulation in Example 3.

[0029] Figure 4 This is the recruitment of dendritic cells at the injection site in Example 4.

[0030] Figure 5This is the maturation and antigen presentation of dendritic cells in lymph nodes in Example 5.

[0031] Figure 6 The IFN-γ secretion capacity of spleen cells in Example 6.

[0032] Figure 7 This is the preventive effect of Pickering emulsion on tumors in Example 7.

[0033] Figure 8 This is the therapeutic effect of Pickering emulsion on tumors in Example 8. DETAILED DESCRIPTION

[0034] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0035] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0036] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0037] The technical principle of the present invention is as follows:

[0038] Monophosphoryl lipid A is an attenuated derivative of lipopolysaccharide produced by Gram-negative bacteria, but it still retains the excellent immune activation ability of lipopolysaccharide. A large number of studies have confirmed that monophosphoryl lipid A can trigger immune cascade responses by binding and recognizing TLR4 receptors on the surface of antigen-presenting cells, thereby mediating innate immunity and adaptive immunity. The recognition and activation of TLR4 receptors by monophosphoryl lipid A is highly dependent on the participation and regulation of multiple proteins, which is mainly determined by the unique chemical structure and properties of monophosphoryl lipid A. Monophosphoryl lipid A is composed of multiple polar long hydrophobic carbon chains and non-polar disaccharide sugar groups, and has an extremely low micelle critical concentration (10 -9mol / L), mainly exists in the form of micro-aggregates in the physiological environment. However, this monophosphoryl lipid A micro-aggregate cannot be directly recognized by the TLR4 receptor. It needs to be first depolymerized into a single molecule with the help of endotoxin binding protein, and then it can correctly recognize and activate the TLR4-MD2 complex, thereby triggering the activation of antigen presenting cells. The inventor believes that in order to enhance the recognition efficiency between monophosphoryl lipid A and TLR4 receptor, continuously maintaining the single molecule state of monophosphoryl lipid A during the delivery process of monophosphoryl lipid A is an important strategy to improve the delivery and recognition efficiency of monophosphoryl lipid A, and, in addition to improving the recognition efficiency by regulating the single molecule state of monophosphoryl lipid A, the recognition efficiency can be further increased by increasing the number of receptor-ligand interactions between monophosphoryl lipid A and TLR4.

[0039] TLR4 is mainly expressed on the cell membrane surface of antigen presenting cells (APCs). Due to the flowable characteristics of the cell membrane system, the TLR4 on its surface is also in a continuous flow state. When the vaccine delivery carrier loaded with monophosphoryl lipid A contacts the APCs cell membrane, the TLR4 outside the contact site can quickly flow to the contact site, thereby continuously replenishing the number of TLR4. The inventor believes that the recognition and activation of TLR4 requires the coordinated participation of monophosphoryl lipid A, and it is difficult to improve the activation efficiency of TLR4 by simply increasing the number of TLR4. Therefore, when the vaccine carrier contacts APCs, the vaccine carrier is also required to have a similar flowable characteristic of the membrane system, so that the monophosphoryl lipid A can be quickly replenished to the contact site, thereby realizing the dynamic recognition effect between monophosphoryl lipid A and TLR4.

[0040] Based on this, the present invention proposes a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A, in which polymer nanoparticles are dispersed at the oil-water interface of the aqueous phase and the oil phase, and the monophosphoryl lipid A is stably distributed at the oil-water interface of the aqueous phase and the oil phase in the form of a single molecule and can flow along the oil-water interface.

[0041] In the Pickering emulsion of the present invention, the immune adjuvant monophosphoryl lipid A is stably distributed in the oil-water interface of the Pickering emulsion in the form of a single molecule, which is conducive to the efficient and correct recognition and activation of the TLR4-MD2 complex by the monophosphoryl lipid A, thereby triggering the activation of antigen presenting cells. The monophosphoryl lipid A can flow laterally at the oil-water interface, increasing the number of receptor-ligand interactions between the monophosphoryl lipid A and TLR4, thereby enhancing the contact and recognition efficiency between the monophosphoryl lipid A and the TLR4 receptor, thereby inducing an efficient cellular immune response.

[0042] The Pickering emulsion used in the present invention is a type of emulsion stabilized by nanoparticles, and its unique oil-water interface structure can provide a structural basis for the single-molecule loading of amphiphilic monophosphoryl lipid A. In addition, compared with traditional emulsions stabilized by surfactants, Pickering emulsions have high stability, low side effects, and good safety. More importantly, Pickering emulsions have deformability or flexibility that rigid particles do not have. During the delivery process, when the Pickering emulsion contacts APCs, it can increase the contact area with APCs by deformation, thereby increasing the uptake efficiency of APCs for the emulsion, thereby increasing the number of receptor-ligand interactions between monophosphoryl lipid A and TLR4.

[0043] Specifically, the present invention provides a method for preparing a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A, comprising:

[0044] S1. adding monophosphoryl lipid A to the oil phase, and using a water bath ultrasound method to completely disperse the monophosphoryl lipid A to obtain a monophosphoryl lipid A-oil phase dispersion;

[0045] S2. adding the monophosphoryl lipid A-oil phase dispersion to an aqueous solution containing polymer nanoparticles and polypeptide antigens to obtain a mixed solution;

[0046] S3. Perform ultrasonic emulsification on the mixed solution to obtain a Pickering emulsion that can achieve efficient delivery of the immune adjuvant monophosphoryl lipid A.

[0047] In step S1 of the present invention, the advantage of using a water bath ultrasound method to completely disperse the monophosphoryl lipid A is that the monophosphoryl lipid A can be quickly dispersed in the oil phase without destroying the structure of the monophosphoryl lipid A.

[0048] In the present invention, in the monophosphoryl lipid A-oil phase dispersion, the mass concentration of the monophosphoryl lipid A is 0.01-0.1%;

[0049] In the aqueous solution containing polymer nanoparticles and polypeptide antigens, the mass concentration of the polymer nanoparticles is 0.11% to 1.1%, and the mass concentration of the polypeptide antigen is 0.003% to 0.03%;

[0050] The volume ratio of the monophosphoryl lipid A-oil phase dispersion to the aqueous solution containing polymer nanoparticles and polypeptide antigens is 1:9.

[0051] In the present invention, the monophosphoryl lipid A in the monophosphoryl lipid A-oil phase dispersion adopts the above concentration, which can fully activate antigen-presenting cells without producing cytotoxicity; the advantage of the polypeptide antigen in the aqueous solution containing polymer nanoparticles and polypeptide antigens adopting the above concentration is that the immune specificity of antigen-presenting cells is fully mobilized without causing immunosuppressive effects; the volume ratio of the monophosphoryl lipid A-oil phase dispersion and the aqueous solution containing polymer nanoparticles and polypeptide antigens is 1:9, which can reduce the viscosity of the emulsion and facilitate injection administration.

[0052] In the Pickering emulsion prepared by the method, the concentration of the polymer nanoparticles in the Pickering emulsion is 0.1-1.0wt%, which can give full play to the emulsion stabilizing ability of the nanoparticles, so that the emulsion maintains a specific particle size distribution and good stability.

[0053] The following will describe in detail a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A and its preparation method and application in combination with examples and experimental data.

[0054] Unless otherwise specified, the reagents or materials described in the following examples are commercially available products.

[0055] Squalene (purity ≥ 98%) and PLGA-based polymers were purchased from Sigma, the peptide antigen SI INFEKL (N-terminal palmitic acid modified) was purchased from Jiangsu GenScript Technology Co., Ltd., and the cell culture medium and fetal bovine serum were purchased from Gibco.

[0056] Example 1

[0057] This embodiment provides a method for preparing a Pickering emulsion that can achieve efficient delivery of the immune adjuvant monophosphoryl lipid A. The specific preparation method is as follows:

[0058] (1) Preparation and characterization of PLGA nanoparticle stabilizers

[0059] Polylactic acid-co-glycolic acid (PLGA) and PEG-coupled block copolymer PLGA-PEG were dissolved in dichloromethane (the concentration of PLGA in dichloromethane was 10 mg / mL) at a certain mass ratio (3:1), and a PVA (2%, w / v) solution was poured in and ultrasonic emulsification was performed to obtain oil-in-water colostrum. The colostrum was then added to another PVA solution and stirred. After the dichloromethane was completely evaporated, the solution was centrifuged to obtain PLGA nanoparticles.

[0060] (2) Lipid modification of peptide antigens

[0061] The class I restricted epitope peptide of ovalbumin (amino acid sequence: SI INFEKL) was used as the model antigen peptide. 2The lipid-modified antigen p al-ESIINFEKL (denoted as pOVA) was prepared by condensation reaction between palmitic acid-COOH (C16-COOH).

[0062] (3) Single-molecule loading of monophosphoryl lipid A in Pickering emulsion

[0063] Adding monophosphoryl lipid A to squalene, and using a water bath ultrasonic method to completely disperse the monophosphoryl lipid A to obtain a monophosphoryl lipid A-oil phase dispersion;

[0064] Adding the monophosphoryl lipid A-oil phase dispersion to the aqueous solution containing the polymer nanoparticles prepared in step (1) and the polypeptide antigen pal-ESI INFEKL to obtain a mixed solution;

[0065] The mixed solution is ultrasonically emulsified to obtain a Pickering emulsion that can achieve efficient delivery of the immune adjuvant monophosphoryl lipid A.

[0066] Among them, in the monophosphoryl lipid A-oil phase dispersion, the mass concentration of monophosphoryl lipid A is 0.05%; in the aqueous solution containing polymer nanoparticles and polypeptide antigens, the mass concentration of polymer nanoparticles is 0.5%, and the mass concentration of the polypeptide antigen is 0.01%; the volume ratio of the monophosphoryl lipid A-oil phase dispersion and the aqueous solution containing polymer nanoparticles and polypeptide antigens is 1:9.

[0067] Among them, the scanning electron microscope image and particle size distribution of Pickering emulsion are as follows Figure 1 As shown. Figure 1 It can be seen that a layer of nanoparticles covers the surface of the emulsion droplets, indicating that the emulsion is indeed a Pickering emulsion. The results of the dynamic light scattering instrument show that the average particle size of the Pickering emulsion is about 1 μm.

[0068] Example 2

[0069] This example detects the existence form of monophosphoryl lipid A in Pickering emulsion.

[0070] The samples prepared in this example were divided into 5 groups: phosphate buffer group (denoted as PBS group);

[0071] The simple mixture group of polypeptide antigen and monophosphoryl lipid A (denoted as pOVA / MPLA group) had a pOVA concentration of 0.01% and a MPLA concentration of 0.005%.

[0072] The simple mixture of Pickering emulsion and monophosphoryl lipid A (denoted as PE+MPLA group) was prepared as follows:

[0073] adding oil phase squalene to an aqueous solution containing PLGA nanoparticles and polypeptide antigens to obtain a mixed solution;

[0074] The mixed solution is ultrasonically emulsified to obtain Pickering emulsion PE, and then an MPLA aqueous solution is added and simply mixed to obtain a PE+MPLA dosage form;

[0075] In the PE+MPLA dosage form, the raw materials and concentrations of each substance were consistent with those of the PMMS group.

[0076] Pickering emulsion group (denoted as PMMS group) that can achieve single molecule delivery of monophosphoryl lipid A;

[0077] The Pickering emulsion group (denoted as MPLA@PEN group) in which monophosphoryl lipid A is loaded in PLGA nanoparticles and stabilized thereby is prepared as follows:

[0078] PLGA polymer nanoparticles encapsulating MPLA (PLGA-MPLA) were prepared by emulsification method;

[0079] adding oil phase squalene to an aqueous solution containing PLGA-MPLA nanoparticles and polypeptide antigens to obtain a mixed solution;

[0080] The mixed solution is subjected to ultrasonic emulsification to obtain Pickering emulsion MPLA@PEN.

[0081] In the MPLA@PEN dosage form, the raw materials and concentrations of each substance are consistent with those of the PMMS group.

[0082] The activation of TLR4 receptors strictly depends on the single molecule state of monophosphoryl lipid A, so the molecular form of monophosphoryl lipid A in Pickering emulsion can be evaluated by detecting the activation efficiency of TLR4 receptors. The specific method is as follows:

[0083] Mouse bone marrow-induced dendritic cells (BMDCs) were used as a cell model to study the activation ability of monophosphoryl lipid A on TLR4 receptors. First, lipopolysaccharide binding protein blocking peptide LBPK95A was added to the cell culture medium to bind to the free lipopolysaccharide binding protein in the culture medium, and then the Pickering emulsion loaded with monophosphoryl lipid A prepared in Example 1 was added. After 6 hours of co-culture, the secretion level of cytokine TNF-α in the cell culture medium was measured to reflect the activation of TLR4 receptors, and the cells without lipopolysaccharide binding protein blocking peptide were used as the control group.

[0084] The cell culture medium contained 10% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 μg / mL streptomycin.

[0085] The sequence of the lipopolysaccharide binding protein blocking peptide LBPK95A is: RVQGRWKVRKSFFK.

[0086] The results are as follows Figure 2As shown, it was shown that the Pickering emulsion PMMS group (ie, the emulsion prepared in Example 1) could increase the secretion of TNF-α by macrophages, which was significantly different from the other groups.

[0087] Example 3

[0088] This example evaluates the activation effect of Pickering emulsion on dendritic cells in vitro.

[0089] The experimental grouping is the same as in Example 2.

[0090] The specific operations are as follows:

[0091] After each group of preparations were co-incubated with BMDCs for 24 h, flow cytometry was used to detect the expression of MHCI-SIINFEKL complex on the surface of BMDCs ( Figure 3 Left figure), thus reflecting the efficiency of antigen cross-presentation. Detecting the expression of co-stimulatory factor CD86 protein on the surface of BMDCs reflects the degree of activation of BMDCs ( Figure 3 right).

[0092] The results are as follows Figure 3 As shown, the PMMS group samples can significantly enhance the antigen cross-presentation and maturation activation ability of BMDCs cells.

[0093] Example 4

[0094] This example evaluates the recruitment of immune cells by the Pickering emulsion at the injection site.

[0095] A total of five experimental groups were set up: PBS group, pOVA / MPLA group, PE+MPLA group, PMMS group and MPLA@PEN group. The specific methods are as follows:

[0096] Each vaccine formulation was subcutaneously injected into 8-week-old C57BL / 6 mice, 100 μL per mouse. 24 hours after injection, each group of mice was killed, and the subcutaneous tissue at the injection site was removed and weighed. The subcutaneous tissue was then placed in PBS and cut into small tissue blocks of about 2-3 mm with scissors. Single cells were collected after collagenase enzymatic hydrolysis, and the number of dendritic cells in the subcutaneous tissue was detected by flow cytometry after antibody staining.

[0097] The C57BL / 6 female mice used in the experiment were provided by Jicui Pharmaceutical Company.

[0098] The results are as follows Figure 4 As shown, Pickering emulsion can significantly increase the number of dendritic cells at the injection site.

[0099] Example 5

[0100] This example evaluates the lymph node activation ability of Pickering emulsion.

[0101] The experimental grouping is the same as in Example 2, and the specific operations are as follows:

[0102] Each group of vaccine preparations was injected subcutaneously into 8-week-old C57BL / 6 mice, 100 μL per mouse. Each group of mice was killed 24 h after injection and processed according to the following steps: ① The draining lymph nodes of the mice were separated and placed in pre-cooled PBS buffer and gently ground with a grinding rod; ② After filtering through a 70-μm cell sieve, a lymph node single cell suspension was obtained; ③ After centrifugation at 500 g for 3 min, the supernatant was discarded and the following flow cytometry staining antibodies were added: CD11c-FI TC, SI INFEKL-H2K b -PE-Cy7, CD86-APC, after staining for 30 minutes, add 1mL PBS buffer, centrifuge at 500g for 3 minutes and discard the supernatant; ④ Add 300μL PBS buffer, suspend and pass through the membrane, and use flow cytometry to detect the maturation and antigen presentation efficiency of dendritic cells in the draining lymph nodes.

[0103] The results are as follows Figure 5 As shown, the Pickering emulsion PMMS group could induce the maturation and antigen presentation of dendritic cells, which were significantly different from those of the other groups.

[0104] Example 6

[0105] This example characterizes the immune responsiveness of the monophosphoryl lipid A Pickering emulsion in a unimolecular form.

[0106] The experimental grouping is the same as in Example 2.

[0107] 100 μL of vaccine preparations of each group were subcutaneously injected into 8-week-old C57BL / 6J mice on days 0 and 14, respectively. 7 days after the second immunization, the mice in each group were killed and processed according to the following steps: ① The mouse spleen was separated in a sterile clean bench and placed in a sterile pre-cooled PBS buffer, and the spleen was gently ground with a grinding rod; ② After filtering through a 70-micron cell sieve, centrifugation (500g, 3min) was performed to obtain a spleen cell pellet; ③ 2mL of red blood cell lysis buffer was added to the spleen cell pellet, and after lysis at room temperature for 4min, 10mL of PBS solution was added to terminate the lysis reaction, and the supernatant was removed after centrifugation (500g, 3min) to obtain spleen cells with complete red blood cell lysis; ④ RPMI 1640 culture medium containing 10% fetal bovine serum and antigen peptide SI INFEKL (2μg / mL) was added to obtain a spleen cell suspension, which was inoculated into a 96-well ELISPOT plate (pre-coated with IFN-γ antibody) and cultured for 24h; ⑤ The cell culture medium was discarded and washed with PBS 5 times, and then R4-6A2-biot incubate for 2 h; ⑥ Wash the plate 5 times with PBS, add Streptavidin-ALP, and incubate at room temperature for 1 h; ⑦ Wash the plate 5 times with PBS, and dry it on absorbent paper after the last wash; ⑧ Add 100 μL BCIP / NBT color development solution to each well and color for 5-10 min in the dark, then pour out the color development solution in the plate and rinse with running water to stop color development; ⑨ After the plate is dried, place it in an ELISPOT spot counter for counting and analysis.

[0108] The results are as follows Figure 6 As shown, the spleen cells in the Pickering emulsion PMMS group could secrete a large amount of cytokine IFN-γ under antigen stimulation, which was significantly different from that in other groups.

[0109] Example 7

[0110] This example evaluates the tumor prevention effect of Pickering emulsion.

[0111] The experimental grouping is the same as in Example 2, and the specific operations are as follows:

[0112] 100 μL of each vaccine preparation was subcutaneously injected into 8-week-old C57BL / 6J mice on days 0, 7, and 14. 5×10 5 E.G7-OVA tumor cells were cultured and the changes in tumor volume of mice in each group were monitored by digital calipers.

[0113] The tumor volume was calculated according to the following formula: Tumor volume (mm 3 ) = length × width × width × 0.5.

[0114] The results are as follows Figure 7 As shown, the Pickering emulsion PMMS group had a significantly better tumor prevention effect than the other groups.

[0115] Example 8

[0116] This example evaluates the tumor therapeutic effect of Pickering emulsion.

[0117] The experimental grouping is the same as in Example 2, and the specific operations are as follows:

[0118] 5×10 5 E.G7-OVA tumor cells were subcutaneously injected into 8-week-old C57BL / 6J mice, and the tumor volume grew to 30-50 mm. 3 At 7-day intervals, 100 μL of the vaccine preparation in each group was subcutaneously injected, and the length and width of the tumor in each group of mice were measured by digital calipers.

[0119] The tumor volume was calculated according to the following formula: Tumor volume (mm 3 ) = length × width × width × 0.5.

[0120] The results are as follows Figure 8 As shown, the inhibitory effect of Pickering emulsion PMMS group on tumor was significantly better than that of other groups.

[0121] In summary, the present invention provides a Pickering emulsion that can achieve single-molecule delivery of monophosphoryl lipid A, which can induce a stronger immune response.

[0122] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0123] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0124] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A Pickering emulsion for efficient delivery of monophosphoryl lipid A, an immune adjuvant. It is characterized in that The Pickering emulsion comprises an oil phase, an aqueous phase, monophosphoryl lipid A, polymer nanoparticles and polypeptide antigens, wherein the polymer nanoparticles and the polypeptide antigens are dispersed at the oil-water interface between the aqueous phase and the oil phase, and the monophosphoryl lipid A is stably distributed at the oil-water interface between the aqueous phase and the oil phase in the form of a single molecule and can flow laterally along the oil-water interface.

2. A Pickering emulsion for achieving efficient delivery of immune adjuvant monophosphoryl lipid A according to claim 1, It is characterized in that The oil phase includes squalene and / or tocopherol, and the aqueous phase includes any one of water, phosphate buffer, citrate buffer and physiological saline.

3. A Pickering emulsion for achieving efficient delivery of immunoadjuvant monophosphoryl lipid A according to claim 1, It is characterized in that The polymer nanoparticles include at least one of PLGA nanoparticles, PEG-modified PLGA nanoparticles, liposomes and ferritin.

4. A Pickering emulsion for achieving efficient delivery of immunoadjuvant monophosphoryl lipid A according to claim 1, It is characterized in that The polypeptide antigen is chemically modified, and the chemical modification includes at least one of alkylation modification, perfluoroalkylation modification, palmitic acid modification, sugar chain modification and PEG modification.

5. A Pickering emulsion for achieving efficient delivery of immunoadjuvant monophosphoryl lipid A according to claim 1, It is characterized in that The Pickering emulsion is an oil-in-water emulsion, and the average particle size of the Pickering emulsion is 500nm to 5μm; The concentration of the polymer nanoparticles in the Pickering emulsion is 0.1 to 1.0 wt %.

6. A method for preparing a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A according to any one of claims 1 to 5, It is characterized in that The preparation method comprises: Adding monophosphoryl lipid A to the oil phase, and using a water bath ultrasound method to completely disperse the monophosphoryl lipid A to obtain a monophosphoryl lipid A-oil phase dispersion; adding the monophosphoryl lipid A-oil phase dispersion to an aqueous solution containing polymer nanoparticles and polypeptide antigens to obtain a mixed solution; The mixed solution is ultrasonically emulsified to obtain a Pickering emulsion that can achieve efficient delivery of the immune adjuvant monophosphoryl lipid A.

7. A method for preparing a Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A according to claim 6, It is characterized in that In the monophosphoryl lipid A-oil phase dispersion, the mass concentration of the monophosphoryl lipid A is 0.01-0.1%; In the aqueous solution containing polymer nanoparticles and polypeptide antigens, the mass concentration of the polymer nanoparticles is 0.11-1.1%, and the mass concentration of the polypeptide antigen is 0.003-0.03%; The volume ratio of the monophosphoryl lipid A-oil phase dispersion to the aqueous solution containing polymer nanoparticles and polypeptide antigens is 1:

9.

8. Use of the Pickering emulsion for achieving efficient delivery of the immune adjuvant monophosphoryl lipid A according to any one of claims 1 to 5 in the preparation of infectious disease vaccines or anti-tumor drugs.

9. The use according to claim 8, It is characterized in that The infectious disease includes any one of influenza, hepatitis B and hand, foot and mouth disease.

10. The use according to claim 8, It is characterized in that The anti-tumor drug includes a drug for preventing or treating any one of lung cancer, melanoma, breast cancer, esophageal cancer, colon cancer, liver cancer and cervical cancer.

Citation Information

Patent Citations

  • Oil-in-water emulsion free of surfactant and use thereof

    CN104013955A

  • Pickering emulsion for co-delivery of antigen and adjuvant as well as preparation method and application of Pickering emulsion

    CN117338716A

  • Pickering emulsion capable of efficiently loading virus particles as well as preparation method and application of Pickering emulsion

    CN117398348A

  • Pickering emulsion delivery system and preparation method and application thereof

    CN118161448A

  • Monophosphoryl lipid adjuvant (MPLA) compositions, vaccine compositions thereof, and methods of preparing and using the same

    WO2023023332A1

Cited By

  • AS04 adjuvant composition for vaccine as well as preparation method and application of AS04 adjuvant composition

    CN121971597A